Armodafinil Improves Simulated Driving and Alertness in Shift Work Disorder

Armodafinil Improves Simulated Driving and Alertness in Shift Work Disorder

Type: Crossover randomized controlled trial

Registration: PMCID: PMC4548520

Status: Published

Tags: Armodafinil, Commute safety, Fatigue & alertness, RCT, Shift Work Disorder (SWD)

External URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC4548520/

Summary

Armodafinil 150 mg taken early in the night shift improved driving simulator performance and alertness in diagnosed SWD, with effects extending into the commute home.

Why It Matters For Night Shift Workers and Night Owls

A crossover RCT whether wake‑ or sleep‑promoting medications found sleep & alertness and driving safety for night‑shift workers and night owls. The effects appear in real shift contexts, clarifying where medicines fit alongside timing strategies instead of replacing them. For people who work nights, that frames an everyday choice (when you eat, how you light the end of a shift, how rest is split) as part of the mechanism, not just routine.

Tags

  • Armodafinil
  • Commute safety
  • Fatigue & alertness
  • RCT
  • Shift Work Disorder (SWD)

Notes

Complementary to Mayo Clin Proc RCTs on modafinil/armodafinil.

← Back to Research